The taug chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the taug chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The taug stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
![]() |
View taug Detailed Price Forecast - CNN Money | ![]() |
View taug Detailed Summary - Google Finance |
![]() |
View taug Detailed Summary - Yahoo! Finance | ![]() |
View taug Stock Research & Analysis - Zacks.com |
![]() |
View taug Trends & Analysis - Trade-Ideas | ![]() |
View taug Major Holders - Barrons |
![]() |
View taug Call Transcripts - NASDAQ | ![]() |
View taug Breaking News & Analysis - Seeking Alpha |
![]() |
View taug Annual Report - CompanySpotlight.com | ![]() |
View taug OTC Short Report - OTCShortReport.com |
![]() |
View taug Fundamentals - TradeKing | ![]() |
View taug SEC Filings - Bar Chart |
![]() |
View Historical Prices for taug - The WSJ | ![]() |
View Performance/Total Return for taug - Morningstar |
![]() |
View the Analyst Estimates for taug - MarketWatch | ![]() |
View the Earnings History for taug - CNBC |
![]() |
View the taug Earnings - StockMarketWatch | ![]() |
View taug Buy or Sell Recommendations - MacroAxis |
![]() |
View the taug Bullish Patterns - American Bulls | ![]() |
View taug Short Pain Metrics - ShortPainBot.com |
![]() |
View taug Stock Mentions - StockTwits | ![]() |
View taug Stock Mentions - PennyStockTweets |
![]() |
View taug Stock Mentions - Twitter | ![]() |
View taug Investment Forum News - Investor Hub |
![]() |
View taug Stock Mentions - Yahoo! Message Board | ![]() |
View taug Stock Mentions - Seeking Alpha |
![]() |
View Insider Transactions for taug - SECform4.com | ![]() |
View Insider Transactions for taug - Insider Cow |
![]() |
View taug Major Holdings Summary - CNBC | ![]() |
View Insider Disclosure for taug - OTC Markets |
![]() |
View Insider Transactions for taug - Yahoo! Finance | ![]() |
View Institutional Holdings for taug - NASDAQ |
![]() |
View taug Stock Insight & Charts - FinViz.com | ![]() |
View taug Investment Charts - StockCharts.com |
![]() |
View taug Stock Overview & Charts - BarChart | ![]() |
View taug User Generated Charts - Trading View |
Tauriga Sciences Inc. Selects First Foods Group, Inc. to Manufacture its New, Full Spectrum CBD Infused Product Line
Posted on Friday March 05, 2021
Tauriga 03-05-2021 Full Spectrum CBD Infused Chocolate Bites This Full Spectrum CBD Infused Product Line contains 25mg per Serving (“Bite”) / 600mg per Jar (“Unit”) NEW YORK, NY, March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has selected First Foods Group, Inc. (OTCQB: FIFG) to manufacture its new, full spectrum CBD infused product line. Through this Manufacturing partnership, First Foods Group, Inc. (“First Foods”) and Tauriga Sciences, Inc. (“Tauriga”) have created a variety of three chocolate-based products – that leverage the capabilities of South East Edibles (First Foods’ flagship brand). The products are comprised of full spectrum CBD infused, chocolate-based candies, that are: Kosher Certified (Orthodox Union), Vegan, Dairy-Free, All Natural, Artisan Crafted. Tauriga’s full spectrum CBD infused product line consists of the following three offerings: White Chocolate with Melatonin + Lavender + Chamomile (Sugar Free) . . . 600mg Full Spectrum CBD per Unit DIABETIC FRIENDLY White Chocolate with Turmeric + Ginger + Lemon + Black Pepper (Sugar Free) . . . 600mg Full Spectrum CBD per Unit DIABETIC FRIENDLY White Chocolate with Coconut Milk (Sugar Based) . . . 600mg Full Spectrum CBD per Unit Tauriga’s CEO Seth M. Shaw expressed, “For the past several months, our management team has been searching for a Manufacturing partner to create an innovative, high quality, full spectrum CBD product line. We are proud to have selected First Foods Group, Inc. with their impressive team and innovation-based approach. Additionally, First Foods is the manufacturer and controls the entire process – and most importantly – the quality assurance protocols. We are continuing to expand our product lines and offerings as we build our customer base and focus on long term growth – with respect to our retail business.” ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com. Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York. About First Foods Group, Inc. First Foods Group, Inc. (OTCQB: FIFG) is a US holding company specializing in the sale of a variety of Cannabidiol (CBD) based products through its subsidiary, Southeast Edibles, based in the USA. Its state-of-the-art facility is based in Fort Lauderdale, FL. Products include infused premium specialty chocolate edibles all made in the USA. First Foods seeks synergistic value through creating its own new concepts, both through proprietary development, mergers, acquisitions and licensing arrangements in the CBD and health and wellness space. Management is committed to an integrated approach using the highest quality hemp solutions and highest purity standards in the industry. First Foods Group Inc, also provides management services and funding options for emerging supplement brands and menu concepts. To learn more about First Foods, please visit our website: https://www.firstfoodsgroup.com To learn more about our Southeast Edibles product line, please visit: https://www.southeastedibles.com DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc.4 Nancy Court, Suite 4Wappingers Falls, NY 12590Chief Executive OfficerMr. Seth M. ShawEmail: sshaw@tauriga.comcell # (917) 796 9926Company Instagram: @taurigumPersonal Instagram: @sethsms47Twitter: @SethMShawCorp. Website: www.tauriga.comE-Commerce Website: www.taurigum.com Attachment Tauriga 03-05-2021
Tauriga Sciences Inc. Acquires Equity Stake in Israeli Biotechnology Firm that Develops Drugs Based on Cannabinoid Molecules
Posted on Monday March 01, 2021
NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has acquired an equity stake in an Israeli biotechnology firm that develops drugs based on Cannabinoid molecules. The Company believes that this equity stake is potentially complementary to its own ongoing Pharmaceutical development efforts (also involving Cannabinoid molecules). The Company plans to File a Form 8-K, within the next several days, to disclose the details of this above-referenced equity stake. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com
Tauriga Sciences Inc. Showcases the Blister Pack Design for its 8th Tauri-Gum SKU, Golden Raspberry Flavor / Vitamin D3 Infused
Posted on Monday March 01, 2021
03_01_2021 PR Image Image of Golden Raspberry Flavor Tauri-gum™ Blister Pack Design Each Piece of Chewing Gum is Infused with 50 Micrograms (“ug”) or 2,000 International Units (“IU”) of Vitamin D3 (“Cholecalciferol”) NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today showcased the Blister Pack design for its 8th Tauri-Gum™ SKU: Golden Raspberry Flavor / Infused with Vitamin D3 (“D3 or Cholecalciferol”). Each piece of chewing gum is in infused with 50 Micrograms (“ug”) or 2,000 International Units (“IU”) of Vitamin D3. The Company now has 3 distinct, Cannabinoid-Free SKUs of Tauri-Gum™ to complement its 5 SKUs of CBD & CBG infused products. These 3 complementary Cannabinoid-Free Tauri-Gum™ SKUs create significant potential opportunities for the Company. In other news, the Company can confirm that it has increased the CBD and CBG infusion concentrations to 25 Milligrams (“mg”) per piece of chewing gum. This takes effect immediately and is incorporated into the Company’s current large production run (as referenced in its press release, dated: February 10, 2021). For this large production run (currently being completed), the Company has allocated $267,750. Lastly, the Company continues to experience overall strength and growth in its highest margin E-Commerce business segment. As of this morning, March 1, 2021, the Company received its 5,515th E-Commerce order. The Tauri-Gum™ Product Line now consists of 8 distinct SKUs: [3] Cannabidiol (“CBD”) Infused SKUs: (i) Color: Red - Pomegranate Flavor (10-25mg) (ii) Color: Orange - Blood Orange Flavor (10-25mg) (iii) Color: Blue - Mint Flavor (10-25mg) [2] Cannabigerol (“CBG”) Infused SKUs: (iv) Color: Yellow - Peach-Lemon Flavor (10-25mg) (v) Color: Purple - Black Currant Flavor (15-25mg) [3] Cannabinoid-Free (Vitamin C + Zinc, Caffeine, Vitamin D3) Infused SKUs: (vi) Color: Green - Pear Bellini Flavor (60mg Vitamin C + 10mg Zinc) (vii) Color: Pink - Cherry Lime Rickey Flavor (50mg Caffeine) (viii) Color: Coral/Gold - Golden Raspberry Flavor (50ug or 2,000 IU) ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment 03_01_2021 PR Image
Tauriga Sciences Inc. Completes Initial Production Run of its Proprietary CBD Infused, Peanut Butter Flavor Pet Treat
Posted on Thursday February 25, 2021
02_25 9_35am EST PR Image Image of Tauri-Pet™ Pouch (30 treats) The Company Expects its Tauri-Pet™ Inventory to Arrive, at its E-Commerce Fulfillment Facility, Within 2-3 Weeks NEW YORK, NY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has completed the initial production run of its proprietary CBD infused, peanut butter flavor pet treat, branded as: Tauri-Pet™. This product is comprised of square shaped, peanut butter flavor, CBD infused dog treats (5mg CBD per treat) – 30 treats per Tauri-Pet™ pouch (150mg CBD total). The proprietary Tauri-Pet™ formulation incorporates the following features: full spectrum CBD, all-natural flavor, premium quality, and made in the USA. The U.S. pet treat market is presently estimated at $7 billion - $10 billion annually, driven by CBD & Other Ingredient trends. The Company plans to develop additional versions of its Tauri-Pet™ product line in the future. The commercial launch of this new product offering will take place via the Company’s E-Commerce website (www.taurigum.com) and potential distribution partners. Link to Tauri-Pet™ on E-Commerce Website (Coming Soon!) https://taurigum.com/products/cbd-dog-treats ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment 02_25 9_35am EST PR Image